Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Anwendungsbeschreibung:
Applications: ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways. ResearchArea: Cancer immunology. Shipping: Ice Bag
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
